- Price
- $105.46
- Day
- -1.55%
- Mkt Cap
- $182.49B
- 52W Range
- $81.97 – $137.49
- Volume
- 5.44M
- Beta
- 0.61
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.
Read full article
Chelsea Counsel Co. decreased its holdings in shares of Abbott Laboratories (NYSE: ABT) by 23.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 16,311 shares of the healthcare product maker's stock after selling 5,000 shares during the period. Chelsea Counsel Co.'s holdings in
Read full article
Abbott Laboratories maintains a diversified business model spanning diagnostics, medical devices, and nutrition products. Eli Lilly is experiencing rapid growth driven by its dominant presence in the cardiometabolic treatment market.
Read full article
Bank of America Corp DE cut its position in Abbott Laboratories (NYSE: ABT) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,279,608 shares of the healthcare product maker's stock after selling 551,015 shares during the quarter. Bank
Read full article
Abbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences. Johnson & Johnson maintains superior net margins and massive scale within its pharmaceutical and medical technology divisions.
Read full article
These companies' recent headwinds shouldn't lead to decreased payouts.
Read full article
ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.
Read full article
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.
Read full article
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill.
Read full article
Abbott Laboratories ABT has a stronger earnings setup after a second-quarter beat and a higher profit outlook. The question is whether that improvement is enough to justify buying the stock with valuation upside looking limited.
Read full article
Bank of Nova Scotia lessened its holdings in shares of Abbott Laboratories (NYSE: ABT) by 16.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,747 shares of the healthcare product maker's stock after selling 52,490 shares during the
Read full article
Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.
Read full article